罗沙司他在肾性贫血治疗中的作用机制及研究进展
Mechanism of Action and Research Progress of Roxadustat in the Treatment of Renal Anemia
DOI: 10.12677/acm.2025.151196, PDF,   
作者: 伍金清：吉首大学医学院，湖南 吉首；吉首大学第四临床学院，湖南 怀化；梅国斌*：吉首大学医学院，湖南 吉首；吉首大学第四临床学院，湖南 怀化；湖南医药学院总医院肾脏内科，湖南 怀化
关键词: 肾性贫血；低氧诱导因子–脯氨酸羟化酶抑制剂；罗沙司他；Renal Anemia； Hypoxia-Inducible Factor-Prolinyl Hydroxylase Inhibitor； Rosastat
摘要: 肾性贫血其发生有着复杂的机制，主要与促红细胞生成素(erythropoiesis, EPO)减少有关。严重贫血可影响患者生活质量并与死亡预后相关。低氧诱导因子-1 (hypoxia inducible factor 1, HIF-1)，可与特定的低氧应答DNA元件结合，调节低氧诱导基因的转录，诱导内源性EPO的产生。近年来，多种低氧诱导因子–脯氨酸羟化酶抑制剂(hypoxia-inducible factor-prolyl hydroxylase inhibitors, HIF-PHIs)被成功开发，其中罗沙司他(Roxadustat, FG-4592)已在中国、日本获准上市，并完成了相关临床试验，已证实罗沙司他可有效提升肾性贫血患者血红蛋白、改善铁代谢及脂代谢。本文就罗沙司他在肾性贫血治疗中的作用机制及研究进展作一综述。
Abstract: The occurrence of renal anemia has a complex mechanism, which is mainly related to the reduction of erythropoiesis (EPO). Severe anemia can affect the quality of life of patients and is associated with the prognosis of death. Hypoxia inducible factor-1 (HIF-1) can bind to specific hypoxia-responsive DNA elements, regulate the transcription of hypoxia-inducible genes, and induce the production of endogenous EPO. In recent years, a variety of hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) have been successfully developed, among which Roxadustat (FG-4592) has been approved for marketing in China and Japan, and relevant clinical trials have been completed. It has been confirmed that Roxadustat can effectively increase hemoglobin, iron metabolism and lipid metabolism in patients with renal anemia. This article reviews the mechanism of action and research progress of Roxadustat in the treatment of renal anemia.
文章引用：伍金清, 梅国斌. 罗沙司他在肾性贫血治疗中的作用机制及研究进展[J]. 临床医学进展, 2025, 15(1): 1464-1470. https://doi.org/10.12677/acm.2025.151196

参考文献

[1] Weiss, G. and Goodnough, L.T. (2005) Anemia of Chronic Disease. New England Journal of Medicine, 352, 1011-1023. [Google Scholar] [CrossRef] [PubMed]
[2] Stauffer, M.E. and Fan, T. (2014) Prevalence of Anemia in Chronic Kidney Disease in the United States. PLOS ONE, 9, e84943. [Google Scholar] [CrossRef] [PubMed]
[3] Kovesdy, C.P., Davis, J.R., Duling, I. and Little, D.J. (2022) Prevalence of Anaemia in Adults with Chronic Kidney Disease in a Representative Sample of the United States Population: Analysis of the 1999-2018 National Health and Nutrition Examination Survey. Clinical Kidney Journal, 16, 303-311. [Google Scholar] [CrossRef] [PubMed]
[4] Eriksson, D., Goldsmith, D., Teitsson, S., Jackson, J. and van Nooten, F. (2016) Cross-Sectional Survey in CKD Patients across Europe Describing the Association between Quality of Life and Anaemia. BMC Nephrology, 17, Article No. 97. [Google Scholar] [CrossRef] [PubMed]
[5] Macdougall, I.C. (2023) Anaemia in CKD—Treatment Standard. Nephrology Dialysis Transplantation, 39, 770-777. [Google Scholar] [CrossRef] [PubMed]
[6] Dulmovits, B.M., Tang, Y., Papoin, J., He, M., Li, J., Yang, H., et al. (2022) Hmgb1-Mediated Restriction of EPO Signaling Contributes to Anemia of Inflammation. Blood, 139, 3181-3193. [Google Scholar] [CrossRef] [PubMed]
[7] Cernaro, V., Lacquaniti, A., Buemi, A., Lupica, R. and Buemi, M. (2014) Does Erythropoietin Always Win? Current Medicinal Chemistry, 21, 849-854. [Google Scholar] [CrossRef] [PubMed]
[8] Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., et al. (2019) Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. New England Journal of Medicine, 381, 1001-1010. [Google Scholar] [CrossRef] [PubMed]
[9] Wang, G.L. and Semenza, G.L. (1995) Purification and Characterization of Hypoxia-Inducible Factor 1. Journal of Biological Chemistry, 270, 1230-1237. [Google Scholar] [CrossRef] [PubMed]
[10] Mokas, S., Larivière, R., Lamalice, L., Gobeil, S., Cornfield, D.N., Agharazii, M., et al. (2016) Hypoxia-Inducible Factor-1 Plays a Role in Phosphate-Induced Vascular Smooth Muscle Cell Calcification. Kidney International, 90, 598-609. [Google Scholar] [CrossRef] [PubMed]
[11] Jaśkiewicz, M., Moszyńska, A., Króliczewski, J., Cabaj, A., Bartoszewska, S., Charzyńska, A., et al. (2022) The Transition from HIF-1 to HIF-2 during Prolonged Hypoxia Results from Reactivation of PHDs and HIF1A mRNA Instability. Cellular & Molecular Biology Letters, 27, Article No. 109. [Google Scholar] [CrossRef] [PubMed]
[12] Salceda, S. and Caro, J. (1997) Hypoxia-Inducible Factor 1α (hif-1α) Protein Is Rapidly Degraded by the Ubiquitin-Proteasome System under Normoxic Conditions: Its Stabilization by Hypoxia Depends on Re-Dox-Induced Changes. Journal of Biological Chemistry, 272, 22642-22647. [Google Scholar] [CrossRef] [PubMed]
[13] Appelhoff, R.J., Tian, Y., Raval, R.R., Turley, H., Harris, A.L., Pugh, C.W., et al. (2004) Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-Inducible Factor. Journal of Biological Chemistry, 279, 38458-38465. [Google Scholar] [CrossRef] [PubMed]
[14] Semenza, G.L. (2001) HIF-1 and Mechanisms of Hypoxia Sensing. Current Opinion in Cell Biology, 13, 167-171. [Google Scholar] [CrossRef] [PubMed]
[15] Czock, D. and Keller, F. (2021) Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat. Clinical Pharmacokinetics, 61, 347-362. [Google Scholar] [CrossRef] [PubMed]
[16] Dhillon, S. (2019) Roxadustat: First Global Approval. Drugs, 79, 563-572. [Google Scholar] [CrossRef] [PubMed]
[17] Akizawa, T., Otsuka, T., Reusch, M. and Ueno, M. (2019) Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐label Study. Therapeutic Apheresis and Dialysis, 24, 115-125. [Google Scholar] [CrossRef] [PubMed]
[18] Chen, N., Hao, C., Liu, B., Lin, H., Wang, C., Xing, C., et al. (2019) Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. New England Journal of Medicine, 381, 1011-1022. [Google Scholar] [CrossRef] [PubMed]
[19] Barratt, J., Andric, B., Tataradze, A., Schömig, M., Reusch, M., Valluri, U., et al. (2021) Roxadustat for the Treatment of Anaemia in Chronic Kidney Disease Patients Not on Dialysis: A Phase 3, Randomized, Open-Label, Active-Controlled Study (DOLOMITES). Nephrology Dialysis Transplantation, 36, 1616-1628. [Google Scholar] [CrossRef] [PubMed]
[20] Fishbane, S., El-Shahawy, M.A., Pecoits-Filho, R., Van, B.P., Houser, M.T., Frison, L., et al. (2021) Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. Journal of the American Society of Nephrology, 32, 737-755. [Google Scholar] [CrossRef] [PubMed]
[21] Fishbane, S., Pollock, C.A., El-Shahawy, M., Escudero, E.T., Rastogi, A., Van, B.P., et al. (2022) Roxadustat versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study. Journal of the American Society of Nephrology, 33, 850-866. [Google Scholar] [CrossRef] [PubMed]
[22] Fort, J., Cuevas, X., Garcia, F., Perez-Garcia, R., Llados, F., Lozano, J., et al. (2010) Mortality in Incident Haemodialysis Patients: Time-Dependent Haemoglobin Levels and Erythropoiesis-Stimulating Agent Dose Are Independent Predictive Factors in the ANSWER Study. Nephrology Dialysis Transplantation, 25, 2702-2710. [Google Scholar] [CrossRef] [PubMed]
[23] Provenzano, R., Shutov, E., Eremeeva, L., Korneyeva, S., Poole, L., Saha, G., et al. (2021) Roxadustat for Anemia in Patients with End-Stage Renal Disease Incident to Dialysis. Nephrology Dialysis Transplantation, 36, 1717-1730. [Google Scholar] [CrossRef] [PubMed]
[24] Liang, Q., Li, X., Niu, Q., Zhao, H. and Zuo, L. (2023) Efficacy and Safety of Roxadustat in Chinese Hemodialysis Patients: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 12, Article No. 2450. [Google Scholar] [CrossRef] [PubMed]
[25] Csiky, B., Schömig, M., Esposito, C., Barratt, J., Reusch, M., Valluri, U., et al. (2021) Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES). Advances in Therapy, 38, 5361-5380. [Google Scholar] [CrossRef] [PubMed]
[26] Wu, W., Hu, N., Li, X., Di, J., Zhou, H., Niu, H., et al. (2024) Influencing Factors of Clinical Efficacy of Roxadustat among Hemodialysis Patients. Renal Failure, 46, Article ID: 2308701. [Google Scholar] [CrossRef] [PubMed]
[27] Tan, W., Wang, X., Sun, Y., Wang, X., He, J., Zhong, L., et al. (2024) Roxadustat Reduces Left Ventricular Mass Index Compared to rHuEPO in Haemodialysis Patients in a Randomized Controlled Trial. Journal of Internal Medicine, 295, 620-633. [Google Scholar] [CrossRef] [PubMed]
[28] 乔敏, 赵传庆, 焉春英, 等. 罗沙司他联合重组人促红素在尿毒症合并肿瘤患者贫血治疗中的疗效[J]. 国际移植与血液净化杂志, 2024, 22(1): 13-14.
[29] 上海市肾内科临床质量控制中心专家组. 慢性肾脏病早期筛查、诊断及防治指南(2022年版) [J]. 中华肾脏病杂志, 2022, 38(5): 453-464.
[30] Groenendaal-van de Meent, D., den Adel, M., van Dijk, J., Barroso-Fernandez, B., El Galta, R., Golor, G., et al. (2018) Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects. European Journal of Drug Metabolism and Pharmacokinetics, 43, 685-692. [Google Scholar] [CrossRef] [PubMed]
[31] Shibata, T., Nomura, Y., Takada, A., Ueno, M., Katashima, M., Yazawa, R., et al. (2018) Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects. Clinical Pharmacology in Drug Development, 8, 304-313. [Google Scholar] [CrossRef] [PubMed]
[32] Provenzano, R., Tumlin, J., Zabaneh, R., Chou, J., Hemmerich, S., Neff, T.B., et al. (2020) Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients. The Journal of Clinical Pharmacology, 60, 1432-1440. [Google Scholar] [CrossRef] [PubMed]
[33] Rekić, D., Kerbusch-Herben, V., Någård, M., Chou, J., Huang, J., Bradley, C., et al. (2021) Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis-and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. Clinical Pharmacokinetics, 60, 759-773. [Google Scholar] [CrossRef] [PubMed]
[34] Shibata, T., Nomura, Y., Takada, A., Aoki, S., Katashima, M. and Murakami, H. (2018) Evaluation of the Effect of Lanthanum Carbonate Hydrate on the Pharmacokinetics of Roxadustat in Non‐Elderly Healthy Adult Male Subjects. Journal of Clinical Pharmacy and Therapeutics, 43, 633-639. [Google Scholar] [CrossRef] [PubMed]
[35] Groenendaal-van de Meent, D., Kerbusch, V., Barroso-Fernandez, B., den Adel, M., van Dijk, J., Golor, G., et al. (2021) Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat after Concomitant or Time-Separated Administration in Healthy Individuals. Clinical Therapeutics, 43, 1079-1091. [Google Scholar] [CrossRef] [PubMed]
[36] Groenendaal‐van de Meent, D., den Adel, M., Kerbusch, V., van Dijk, J., Shibata, T., Kato, K., et al. (2022) Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results from 3 Phase 1, Open‐Label, 1‐Sequence, Crossover Studies. Clinical Pharmacology in Drug Development, 11, 486-501. [Google Scholar] [CrossRef] [PubMed]
[37] Barratt, J., Dellanna, F., Portoles, J., Choukroun, G., De Nicola, L., Young, J., et al. (2023) Safety of Roxadustat versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-Dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Advances in Therapy, 40, 1546-1559. [Google Scholar] [CrossRef] [PubMed]
[38] Akizawa, T., Yamaguchi, Y., Otsuka, T., et al. (2020) A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis. Nephron, 144, 372-382. [Google Scholar] [CrossRef] [PubMed]
[39] Shi, X.T., Li, M., Cui, W.X., et al. (2022) Hypothyrotropin Hypothyroidism Caused by Roxadustat: A Case Report. Chinese Journal of Internal Medicine, 61, 1357-1359.
[40] Yao, B., Wei, Y., Zhang, S., Tian, S., Xu, S., Wang, R., et al. (2019) Revealing a Mutant-Induced Receptor Allosteric Mechanism for the Thyroid Hormone Resistance. iScience, 20, 489-496. [Google Scholar] [CrossRef] [PubMed]
[41] Tokuyama, A., Kadoya, H., Obata, A., Obata, T., Sasaki, T. and Kashihara, N. (2021) Roxadustat and Thyroid-Stimulating Hormone Suppression. Clinical Kidney Journal, 14, 1472-1474. [Google Scholar] [CrossRef] [PubMed]
[42] Omote, D., Kuramoto, N., Tomikawa, A., Yasui, M., Fukuta, M. and Hiraguri, M. (2024) Roxadustat-Induced Central Hypothyroidism in Renal Anemia Patients: Insights from Antineutrophil Cytoplasmic Antibody-Related Vasculitis Cases. Cureus, 16, e61843. [Google Scholar] [CrossRef] [PubMed]
[43] Zheng, X., Jin, Y., Xu, T., Xu, H. and Zhu, S. (2023) Thyroid Function Analysis after Roxadustat or Erythropoietin Treatment in Patients with Renal Anemia: A Cohort Study. Renal Failure, 45, Article ID: 2199093. [Google Scholar] [CrossRef] [PubMed]
[44] Cheng, Y., Xiang, Q., Cao, T., Tang, F., Chen, J., Qi, D., et al. (2023) Suppression of Thyroid Profile during Roxadustat Treatment in Chronic Kidney Disease Patients. Nephrology Dialysis Transplantation, 38, 1567-1570. [Google Scholar] [CrossRef] [PubMed]
[45] Li, N., Cui, W., Mu, D., Shi, X., Gao, L., Liu, S., et al. (2024) Effects of Roxadustat on Thyroid Hormone Levels and Blood Lipid Metabolism in Patients Undergoing Hemodialysis: A Retrospective Study. International Journal of Medical Sciences, 21, 1806-1813. [Google Scholar] [CrossRef] 

为你推荐